Leukemia Research Reports (Jan 2021)
Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
- Masaya Abe,
- Nobuharu Fujii,
- Kentaro Mizuhara,
- Tomohiro Urata,
- Yuichi Sumii,
- Yuki Fujiwara,
- Keisuke Seike,
- Yasuhisa Sando,
- Makoto Nakamura,
- Keiko Fujii,
- Kyosuke Saeki,
- Yusuke Meguri,
- Noboru Asada,
- Daisuke Ennishi,
- Hisakazu Nishimori,
- Ken-ichi Matsuoka,
- Yoshinobu Maeda
Affiliations
- Masaya Abe
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Nobuharu Fujii
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan; Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan; Corresponding author: Nobuharu Fujii, Department of Hematology and Oncology, Okayama University Hospital Address: 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan.
- Kentaro Mizuhara
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Tomohiro Urata
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Yuichi Sumii
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Yuki Fujiwara
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Keisuke Seike
- Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Yasuhisa Sando
- Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Makoto Nakamura
- Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Keiko Fujii
- Department of Transfusion Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Kyosuke Saeki
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Yusuke Meguri
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Noboru Asada
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Daisuke Ennishi
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Hisakazu Nishimori
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Ken-ichi Matsuoka
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Yoshinobu Maeda
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture 700-8558, Japan
- Journal volume & issue
-
Vol. 15
p. 100241
Abstract
Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.
